Single-dose pharmacokinetics of indinavir and the effect of food

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 2, 1998, Pages 332-338

  Yeh, Kuang C ^a   Deutsch, Paul J ^a   Haddix, Heidi ^a   Hesney, Michael ^a   Hoagland, Vicki ^a   Ju, William D ^a   Justice, Steven J ^a   Osborne, Barbara ^b   Sterrett, Andrew T ^a   Stone, Julie A ^a   Woolf, Eric ^a   Waldman, Scott ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERANCE; DRUG URINE LEVEL; FOOD DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ANALYSIS OF VARIANCE; DIETARY FATS; DOUBLE-BLIND METHOD; FOOD-DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; METABOLIC CLEARANCE RATE;

EID: 0031942263     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Balani, S. K., B. H. Arison, L. Mathai, L. R. Kaufman, R. R. Miller, R. A. Sterns, I. W. Chen, and J. H. Lin. 1995. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab. Dispos. 23:266-270.
2. Balani, S. K., E. J. Woolf, M. Sturgill, P. J. Deutsch, K. C. Yeh, and J. H. Lin. 1996. Disposition of indinavir, a potent HIV-1 protease inhibitor, after oral dose in humans. Drug Metab. Dispos. 24:1389-1394.
3. Bjornsson, T., R. Chiou, P. Deutsch, H. Haddix, V. Hoagland, S. Justice, M. Nessly, R. Pomerantz, M. Saag, K. Squires, H. Teppler, S. Waldman, E. Woolf, and K. C. Yeh. 1996. Pharmacokinetics of indinavir. Pharm. Res. 13:S485.
4. Chiba, M., M. Hensleigh, J. A. Nishime, K. S. Balani, and J. H. Lin. 1996. Role of CYP3A4 in human metabolism of MK-639, a potent HIV protease inhibitor. Drug Metab. Dispos. 24:307-314.
5. Chiou, R., P. Deutsch, A. Carides, I. Fu, G. Kwei, V. Hoagland, G. Lambert, M. Sturgill, and K. C. Yeh. 1996. Indinavir absorption following extended-release formulations in man and in the dog. Pharm. Res. 13:S498.
6. Daudon, M., L. Estepa, J. P. Viard, P. Joly, and P. Jungers. 1997. Urinary stones in HIV-1 positive patients treated with indinavir. Lancet 349:1294-1295.
7. Debouck, C. 1992. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum. Retroviruses 8:153-164.
8. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, J. A. Chodakewitz, P. J. Deutsch, D. Holder, W. A. Schleif, and J. H. Condra. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
9. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, J. E. Feinberg, H. H. Balfour, L. R. Deyton, J. A. Chodakewitz, M. A. Fischl, J. P. Phair, W. Spreen, L. Pedneault, B. Y. Nguyen, J. C. Cook, and ACTG 320 Study Team. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725-733.
10. Huff, J. R. 1991. HIV protease: a novel chemotherapeutic target for AIDS. J. Med. Chem. 34:2305-2314.
11. Huff, J. R., J. R. Vacca, B. D. Dorsey, E. A. Emini, J. H. Condra, W. A. Schleif, F. E. Massari, P. J. Deutsch, J. Chodakewitz, L. C. Kuo, and Z. Chen. 1996. Crixivan®: a potent inhibitor of HIV-1 protease in vivo, abstr. Medi-255. In Abstracts of the 211th ACS National Meeting.
12. Kirk, J. K. 1995. Significant drug-nutrient interactions. Am. Fam. Physician 51:1175-1182.
13. Kopp, J. B., K. D. Miller, J. A. M. Mican, I. M. Feuerstein, E. Vaughan, C. Baker, L. K. Pannell, and J. Falloon. 1997. Crystalluria and urinary tract abnormalities associated with indinavir. Ann. Intern. Med. 127:119-125.
14. Kwei, G. Y., L. B. Novak, L. A. Hettrick, E. R. Reiss, D. Ostovic, A. E. Loper, C. Y. Lui, R. J. Higgins, I. W. Chen, and J. H. Lin. 1995. Regiospecific intestinal absorption of HIV protease inhibitor L-735,524 in beagle dogs. Pharm. Res. 12:884-888.
15. Lin, J. H., I. W. Chen, K. J. Vastag, and D. Ostovic. 1995. pH-dependent oral absorption of L-735,524, a potent HIV-protease inhibitor, in rats and dogs. Drug Metab. Dispos. 23:730-735.
16. Lin, J. H., M. Chiba, S. K. Balani, I. W. Chen, G. Y.-S. Kwei, K. J. Vastag, and J. A. Nishime. 1996. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24:1111-1120.
17. Medical Economics Co. 1997. Physician's desk reference, vol. 51, p. 1670-1673. Medical Economics, Montvale, N.J.
18. Medical Economics Co. 1997. Physician's desk reference, vol. 51, p. 2291-2294. Medical Economics Co., Montvale, N.J.
19. Medical Economics Co. 1997. Physician's desk reference, vol. 51, p. 447-451. Medical Economics Co., Montvale, N.J.
20. Merck Research Laboratories. Data on file. Merck Research Laboratories, West Point, Pa.
21. Quart, B. D., S. K. Chapman, J. Peterkin, S. Webber, and S. Oliver. 1995. Phase 1 safety, tolerance, pharmacokinetics and food effect studies of AG1343, abstr. LB3. In Abstracts of the 2nd National Conference on Human Retrovirus and Related Infections.
22. Robert, N. A., J. A. Marin, D. Kinchington, A. V. Broadhurst, J. C. Craig, I. B. Duncan, S. A. Galpin, B. K. Handa, J. Kay, A. Krohn, E. W. Lambert, J. H. Merrett, J. S. Mills, K. E. B. Parkes, S. Redshaw, A. J. Ritchie, D. L. Taylor, G. J. Thomas, and P. J. Machin. 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361.
23. Rowland, M., and T. N. Tozer. 1995. Clinical pharmacokinetics, 3rd ed., p. 174. Lea & Febiger, Philadelphia, Pa.
24. Shaw, T. M., P. E. O. Williams, G. J. Nuirhead, S. Harris, N. Watson, and W. Nimmo. 1993. Effect of timing of food and gastric pH on exposure to Ro31-8959, HIV proteinase inhibitor in healthy subjects, abstr. PO-B30-2199. p. 502. In Abstracts of the International Conference on AIDS.
25. Squires, K. E., M. S. Saag, H. Teppler, R. Pomerantz, S. Waldman, T. Bjornsson, E. Woolf, K. Yeh, E. Emini, and P. Deutsch. 1994. Phase I studies of L-735,524, an HIV protease inhibitor: pharmacokinetics, tolerability and short-term antiviral activity. Clin. Res. 42:280A.
26. Steigbigel, R. T., P. Berry, J. Mellors, D. McMahon, H. Teppler, D. Stein, G. Drusano, P. Deutsch, K. Yeh, C. Hildebrand, M. Nessly, E. Emini, and J. Chodakewitz. 1996. Efficacy and safety of the HIV protease inhibitor indinavir sulfate (MK-639) at escalating dose. In Proceedings of the 3rd Conference on Retroviruses and Opportunistic Infections.
27. Stein, D. S., D. G. Fish, J. A. Bilello, S. L. Preston, G. L. Martineau, and G. L. Drusano. 1996. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 10:485-492.
28. Stelmach, C., and D. Ostovic. 1996. Physical and chemical characterization of the HIV protease inhibitor Crixivan®. Pharm. Res. 13:S280.
29. Stone, J. A., W. D. Ju, A. Sterritt, E. J. Woolf, K. C. Yeh, P. Deutsch, S. Waldman, and T. D. Bjornsson. 1996. Effect of food on the pharmacokinetics of indinavir in man. Pharm. Res. 13:S414.
30. Thomas, J. A. 1995. Drug-nutrient interactions. Nutr. Res. 53:271-282.
31. Vacca, J. P., B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, P. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Holloway, J. Lin, I. W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, and J. E. Hoff. 1994. L-735,524, an orally bioavailable HIV-1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
32. Waldman, S. A., H. Teppler, B. Osborne, T. D. Bjornsson, R. Pomerantz, E. Woolf, K. Yeh, P. Deutsch, K. Squires, and M. Saag. 1994. Pharmacokinetics of L-735,524, an HIV protease inhibitor. Clin. Pharmacol. Ther. 55:195.
33. Welling, P. G. 1989. Effect of food on drug absorption. Pharmacol. Ther. 43:425-441.
34. Winstanley, P. A., and M. L. E. Orme. 1989. The effect of food on drug bioavailability. Br. J. Clin. Pharmacol. 28:621-628.
35. Woolf, E., T. Au, H. Haddix, and B. Matuszewski. 1995. Determination of L-735,524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via HPLC with column switching. J. Chromatogr. 692:45-52.
36. Yeh, K. C., and R. D. Small. 1989. Pharmacokinetic evaluation of stable piecewise cubic polynomials as numerical integration functions. J. Pharmacokinet. Biopharm. 17:721-740.